Anti-infective use in children and pregnancy: current deficiencies and future challenges.
暂无分享,去创建一个
[1] B. Guglielmo,et al. Desired Vancomycin Trough Serum Concentration for Treating Invasive Methicillin-resistant Staphylococcal Infections , 2013, The Pediatric infectious disease journal.
[2] B. Pasternak,et al. Use of oral fluconazole during pregnancy and the risk of birth defects. , 2013, The New England journal of medicine.
[3] A. Riordan,et al. Vancomycin dosing in children: what is the question? , 2013, Archives of Disease in Childhood.
[4] A. Shennan,et al. The challenges of licensing drugs for use in pregnancy , 2013, Expert opinion on pharmacotherapy.
[5] Mehul Dhorda,et al. Pharmacokinetic Properties of Artemether, Dihydroartemisinin, Lumefantrine, and Quinine in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria in Uganda , 2013, Antimicrobial Agents and Chemotherapy.
[6] C. Rayner,et al. Pharmacokinetic-Pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation Studies , 2013, Antimicrobial Agents and Chemotherapy.
[7] C. Staatz,et al. Population Pharmacokinetics of Tobramycin in Patients With and Without Cystic Fibrosis , 2013, Clinical Pharmacokinetics.
[8] Talene A. Metjian,et al. The Use of Intravenous Colistin Among Children in the United States: Results From a Multicenter, Case Series , 2013, The Pediatric infectious disease journal.
[9] A. Zolopa,et al. Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment‐naïve HIV‐1‐infected patients , 2012 .
[10] Kassoum Kayentao,et al. Safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy: a systematic review , 2012, Malaria Journal.
[11] E. Alp,et al. Old agent, new experience: colistin use in the paediatric Intensive Care Unit--a multicentre study. , 2012, International journal of antimicrobial agents.
[12] U. d’Alessandro,et al. A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy , 2012, Malaria Journal.
[13] M. Kamya,et al. Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study , 2012, Journal of the International AIDS Society.
[14] J. Korth-Bradley,et al. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. , 2012, Clinical therapeutics.
[15] J. Roberts,et al. The Clinical Relevance of Plasma Protein Binding Changes , 2012, Clinical Pharmacokinetics.
[16] O. Dawod,et al. Effect of quinine therapy on plasma glucose and plasma insulin levels in pregnant women infected with Plasmodium falciparum malaria in Gezira state. , 2011, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.
[17] Thomas M. English,et al. Assessment of Vancomycin Dosing and Subsequent Serum Concentrations in Pediatric Patients , 2011, The Annals of pharmacotherapy.
[18] C. Oudin,et al. Vancomycin prescription in neonates and young infants: toward a simplified dosage , 2011, Archives of Disease in Childhood: Fetal and Neonatal Edition.
[19] Sara E Cosgrove,et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] F. Nosten,et al. Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. , 2010, The Lancet. Infectious diseases.
[21] S. Talungchit,et al. Effects of long-term use of HAART on oral health status of HIV-infected subjects. , 2010, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[22] H. Derendorf,et al. Pharmacokinetic/Pharmacodynamic Profile of Posaconazole , 2010, Clinical pharmacokinetics.
[23] Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase - United States, 2010. , 2010, MMWR. Morbidity and mortality weekly report.
[24] K. Stoltze,et al. Hyposalivation, xerostomia and oral health status of HIV-infected subjects in Thailand before HAART era. , 2010, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[25] Organización Mundial de la Salud. Guidelines for the treatment of malaria , 2010 .
[26] M. Falagas,et al. Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. , 2009, International journal of antimicrobial agents.
[27] C. Dollfus,et al. Correction of facial lipoatrophy using autologous fat transplants in HIV‐infected adolescents , 2009, HIV medicine.
[28] Nawal M. Nour,et al. Malaria and pregnancy: a global health perspective. , 2009, Reviews in obstetrics & gynecology.
[29] F. Nosten,et al. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria , 2009, European Journal of Clinical Pharmacology.
[30] H. Sørensen,et al. Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. , 2008, The Journal of antimicrobial chemotherapy.
[31] Paige L. Williams,et al. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] F. Nosten,et al. Pharmacokinetic study of artemether–lumefantrine given once daily for the treatment of uncomplicated multidrug‐resistant falciparum malaria , 2007, Tropical medicine & international health : TM & IH.
[33] L. Gustafsson,et al. Pharmacokinetics of quinine and its metabolites in pregnant Sudanese women with uncomplicated Plasmodium falciparum malaria , 2007, Journal of clinical pharmacy and therapeutics.
[34] J. Massie,et al. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis , 2006, Journal of paediatrics and child health.
[35] C. Whitty,et al. REVIEW: Malaria in pregnancy , 2005, BJOG : an international journal of obstetrics and gynaecology.
[36] M. J. García-Miguel,et al. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children , 2005, European Journal of Pediatrics.
[37] Yusuke Tanigawara,et al. MICROMEDEX® Healthcare Series , 2004 .
[38] Azza,et al. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe , 2004, AIDS.
[39] J. N. van den Anker,et al. Vancomycin: pharmacokinetics and administration regimens in neonates. , 2004, Clinical pharmacokinetics.
[40] Rodolphe Thiébaut,et al. Combination antiretroviral therapy and the risk of myocardial infarction , 2003 .
[41] J. Niebyl. Antibiotics and Other Anti-infective Agents in Pregnancy and Lactation , 2003, American journal of perinatology.
[42] Susan M Abdel-Rahman,et al. Developmental pharmacology--drug disposition, action, and therapy in infants and children. , 2003, The New England journal of medicine.
[43] G. McComsey. Metabolic complications of antiretroviral therapy in children , 2003, The Pediatric infectious disease journal.
[44] C. Kozinetz,et al. Lipodystrophy syndrome in human immunodeficiency virus-infected children , 2002, The Pediatric infectious disease journal.
[45] J. Rotschafer,et al. What Do We Really Know About Antibiotic Pharmacodynamics? , 2001, Pharmacotherapy.
[46] S. Krudsood,et al. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. , 2001, The American journal of tropical medicine and hygiene.
[47] H. Sørensen,et al. Risk of malformations and other outcomes in children exposed to fluconazole in utero. , 1999, British journal of clinical pharmacology.
[48] D. Cooper,et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.
[49] G. Koren,et al. Pharmacokinetic Changes During Pregnancy and Their Clinical Relevance , 1997, Clinical pharmacokinetics.
[50] D. Bartley,et al. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. , 1997, American journal of medical genetics.
[51] J. Abraham,et al. Fluconazole-induced congenital anomalies in three infants. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[52] P. Routledge. Pharmacokinetics in children. , 1994, The Journal of antimicrobial chemotherapy.
[53] J. D. De MELLO. MALARIA IN PREGNANCY , 1983, The Lancet.